Presentation of Biomarker Analysis at ASCO
Faron Pharmaceuticals Ltd (“Faron or Company”) Faron Announces Presentation of Biomarker Analysis at 2022 ASCO Annual Meeting Showing PromisingClinical Benefit of Bexmarilimab in Patients with Low PD-L1 and High Clever-1 Levels · Biomarker analyses indicate that the tumors of patients benefitting from treatment with bexmarilimab had: · statistically significant higher levels of Clever-1 positive intra-tumoral cells · low PD-L1 levels, a population that does not typically respond to or is ineligible for treatment with currently approved checkpoint inhibitors